Moderate

Allergic contact dermatitis in children

Contact dermatitis · Dermatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Delayed (type IV) hypersensitivity producing an itchy, erythematous, scaly (± vesicular/bullous in acute forms) dermatitis localised to sites of allergen contact, appearing 1–3 days (sometimes longer) after exposure. Up to 20% of children with atopic dermatitis have concomitant ACD. DRAFT for clinician review.

Red flags

  • Facial/periorbital or widespread involvement
  • Secondary bacterial infection
  • Failure to clear with avoidance (reconsider diagnosis or systemic allergen)
  • Severe diaper-area dermatitis

Assessment

Differential diagnosis

  • Atopic dermatitis (flexural; most common pediatric dermatosis)
  • Irritant contact dermatitis (stinging/burning, irritant history e.g. lip-licking, handwashing)
  • Psoriasis (extensor, silvery scale, Auspitz sign)
  • Seborrheic dermatitis (greasy yellow scale; cradle cap in infants)

Investigations

  • Clinical, based on distribution matching an allergen contact site (hands/feet, face, shin, diaper area)
  • Patch testing is the gold standard (outpatient; can be done in young children)
  • If positive nickel patch with no obvious contact source, consider systemic (dietary) nickel exposure

Management

  • Identify and avoid the allergen (mainstay) — counsel caregivers; ACDS Contact Allergy Management Program (CAMP) resource
  • Barrier measures (100% petrolatum; moistened towel instead of wipes for diaper area)
  • Topical corticosteroid for limited acute disease
  • Topical calcineurin inhibitor / PDE4 / JAK as alternatives for prolonged treatment or sensitive sites
  • Systemic steroid for severe/widespread acute ACD
  • Expect clearance in 6–8 weeks of avoidance (up to 16 weeks); if no improvement, reconsider patch-test relevance, systemic exposure, or alternate diagnosis

Drugs & doses

Medium-to-high-potency topical corticosteroid — once–twice daily for up to 2–4 weeks (limited acute ACD). On face/flexural areas and in younger children, use medium potency for up to 2 weeks.
Topical calcineurin inhibitor, topical PDE4 inhibitor (crisaborole, approved ≥3 months of age), or topical JAK — alternatives for prolonged treatment (4–6 weeks) or sensitive sites / documented steroid ACD.
Topical ruxolitinib (JAK) — option in children >12 years; restrict to <20% of body surface area and <60 g/week.
Oral prednisone for severe or widespread acute ACD — 1–2 mg/kg/day tapered over 14–21 days (e.g. a 40 kg child with severe poison-ivy ACD: 40 mg × 7 days, then 30 mg × 7 days, then 20 mg × 7 days).
Prescription mupirocin — safe topical antibiotic alternative in children allergic to bacitracin/neomycin.

Disposition

Discharge with allergen-avoidance counselling and topical therapy; refer to dermatology/allergy for patch testing. Short admission rarely needed for severe/superinfected disease.

Complications & pitfalls

  • Secondary bacterial infection
  • Post-inflammatory dyspigmentation
  • Chronic/recurrent dermatitis from unavoidable exposure
  • Nutritional deficiency if an over-restrictive low-nickel diet is imposed

Exam pearls

  • Localisation to a contact site is the diagnostic clue; autoeczematization ('id') can cause spread
  • Common pediatric allergens: fragrances/hydroperoxides of linalool, methylisothiazolinone, formaldehyde releasers, neomycin, bacitracin, nickel
  • Neomycin cross-reacts with other aminoglycosides and with bacitracin
  • A <2-week oral steroid burst often causes poison-ivy rebound — taper over 2–3 weeks
  • Adult 'Acute severe contact dermatitis' is already covered as a separate entry

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.